Key Highlights: Tegoprazan is the first and only P-CAB reported to demonstrate clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a prospective U.S. phase 3 clinical trial. Detailed analysis from the randomized, double-blind, placebo-controlled Phase 3...
Hence then, the article about sebela pharmaceuticals to present positive phase 3 tegoprazan data in non erosive reflux disease nerd at the american college of gastroenterology acg 2026 meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting )
Also on site :
- Sci-Fi Thriller ‘Overstake’ Gets Generative AI Rebuild, Boarded by Cappu Films at Busan Market (EXCLUSIVE)
- Wyoming Panel Backs Felony Penalty for Online Sweepstakes
- Gardeners Say You Can Still Plant These 8 Vegetables in November—With the Right Conditions for a Future Harvest